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KEY MESSAGES 
What is the key question? 
Which pneumococcal serotypes are implicated in adult pneumococcal pneumonia and which patient 
groups are associated with vaccine-serotype disease? 
What is the bottom line? 
The incidence of pneumococcal CAP is increasing, predominantly due to non-vaccine serotypes and 
serotype 3. Novel pneumococcal vaccines targeting emerging serotypes are needed.. PCV13-
serotype pneumonia (dominated by serotype 3) is more likely in patients in the UK pneumococcal 
vaccination clinical risk group while PPV23-serotype pneumonia is more likely in patients outside the 
clinical risk group. 
Why read on? 
This large prospective cohort study is the first to describe pneumococcal serotype trends and clinical 
risk groups in adult patients with community-acquired pneumonia in UK using a novel and validated 
multiplex immunoassay.  
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ABSTRACT (limit 250 words) 
Background. Changes over the last five years (2013–2018) in the serotypes implicated in adult 
pneumococcal pneumonia and the patient groups associated with vaccine-type disease are largely 
unknown.  
Methods.  We conducted a population-based prospective cohort study of adults admitted to two 
large university hospitals with community-acquired pneumonia (CAP) between September 2013 and 
August 2018. Pneumococcal serotypes were identified using a novel 24-valent urinary monoclonal 
antibody assay and from blood cultures. Trends in incidence rates were compared against national 
invasive pneumococcal disease (IPD) data. Persons at risk of vaccine-type pneumonia (PCV13 and 
PPV23) were determined from multivariate analyses. 
Findings. Of 2934 adults hospitalised with CAP, 1075 (36·6%) had pneumococcal pneumonia. The 
annual incidence of pneumococcal pneumonia increased from 32·2 to 48·2 per 100,000 population 
(2013-2018), predominantly due to increases in PCV13non7- and non-vaccine type (NVT)-serotype 
pneumonia (annual IRR 1·12, 95% CI 1·04-1·21 and 1·19, 95% CI 1·10-1·28 respectively). Incidence 
trends were broadly similar to IPD data. PCV13non7 (56·9% serotype 3) and PPV23non13 (44·1% 
serotype 8) serotypes were identified in 349 (32·5%) and 431 (40·1%) patients with pneumococcal 
pneumonia respectively. PCV13-serotype pneumonia (dominated by serotype 3) was more likely in 
patients in the UK pneumococcal vaccination clinical risk group (aOR 1·73, 95% CI 1·31-2·28) while 
PPV23-serotype pneumonia was more likely in patients outside the clinical risk group (aOR 1·54, 95% 
CI 1·13-2·10). 
Interpretation. The incidence of pneumococcal CAP is increasing, predominantly due to NVT 
serotypes and serotype 3. PPV23-serotype pneumonia is more likely in adults outside currently 
identified clinical risk groups. 
 
(248 words) 
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INTRODUCTION 
Pneumococcal conjugate vaccines (PCVs) have demonstrated substantial effectiveness in reducing 
pneumococcal disease due to vaccine serotypes.1,2 In England and Wales, immunisation of children 
with a 7-valent pneumococcal conjugate vaccine (PCV7) commenced in 2006 and was replaced in 
April 2010 with a 13-valent pneumococcal conjugate vaccine (PCV13).3 Over the same period,  
individuals aged >2 years with a clinical risk factor for pneumococcal disease and all adults aged ≥65 
years have been offered vaccination with the 23-valent pneumococcal polysaccharide vaccine 
(PPV23).3 
Both PCVs have been associated with rapid and sustained reductions in overall and vaccine-serotype 
invasive pneumococcal disease (IPD) in young children.4 PCVs also reduce carriage in vaccinated 
individuals and hence prevent onward transmission to unvaccinated older children and adults. Thus, 
reductions in IPD and pneumococcal pneumonia have been observed across all age groups.4-7 
Since 2013/14, however, overall IPD incidence due to PCV13 serotypes has plateaued in the UK, 
while IPD due to non-PCV serotypes has increased rapidly, especially in adults and the elderly.2,4 The 
USA by contrast, where PCV13 has been recommended as part of the childhood immunisation 
programme since 2010, has not observed such an increase in non-PCV13-serotype IPD despite large 
declines in PCV13-serotype disease.8 
In adults, IPD accounts for less than 10% of pneumococcal pneumonia cases. There are therefore 
limited contemporary data on the range of serotypes causing pneumococcal pneumonia in adults in 
the UK.7 In particular, the contribution of PCV13 and PPV23 serotypes to pneumococcal pneumonia 
is important to inform national pneumococcal vaccine policy, especially in adults and the elderly.9,10 
Since 2008, we have conducted a prospective population-based adult pneumococcal pneumonia 
study to determine changes in clinical disease and the responsible pneumococcal serotypes.7,11 
Recently, a novel, validated 24-valent multiplex urinary immunoassay was developed to detect PCV 
and PPV serotypes in patients with non-invasive disease.12 We report the use of this assay in a 
previously unreported cohort of patients to describe a) serotype trends in adult pneumococcal 
pneumonia since PCV13 replaced PCV7, and b) the clinical risk groups associated with vaccine-type 
disease.  
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METHODS 
Study design  
We conducted a prospective observational cohort study of consecutive adult patients admitted to 
two large university hospitals with CAP between September 2013 and August 2018. Together, these 
two hospitals cover the catchment for emergency admissions in the Greater Nottingham area. All 
patients admitted to acute admission areas were screened for study eligibility every weekday. 
Patients aged ≥16 years presenting with one or more symptom suggestive of lower respiratory tract 
infection (LRTI; defined as cough, increasing dyspnoea, sputum production, and fever), with 
evidence of acute infiltrates consistent with respiratory infection on admission radiography, and 
treated for a diagnosis of CAP were eligible. Exclusion criteria included hospitalisation within 10 days 
of index admission, a diagnosis of tuberculosis, or post-obstructive pneumonia. Informed consent 
was obtained from all study participants; if patients lacked capacity, proxy consent was sought from 
patient personal consultees. Demographic and clinical characteristic data were collected using a 
standardised proforma. Study procedures were approved by the Nottingham Research Ethics 
Committee (REC reference 08/H0403/80). 
Microbiology 
Baseline microbiological investigations were performed at the discretion of the clinical team. In 
addition, urine samples for pneumococcal specific microbiological analyses were obtained within 72 
hours of admission; Binax-NOW® (Alere, Stockport, UK) assay for pneumococcal C-polysaccharide 
urinary antigen detection (UAD) was performed in the local microbiological laboratory,13 with the 
remaining volume of urine frozen at -80oC and batch transported to Public Health England (PHE)’s 
Respiratory and Vaccine Preventable Bacteria Reference Unit (RVPBRU) in Colindale, London for 
pneumococcal serotyping using a validated multiplex immunoassay (Bio-plex24.) The Bio-plex24 
assay targets the detection of pneumococcal serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and the pneumococcal cell-wall polysaccharide.12 
Samples from September 2014 to August 2015 were tested using the original protocol as published 
by Eletu et al, with a clinical sensitivity of 96·2%, specificity 89·9%.12 The assay was then updated to 
include minor protocol modifications and alternative monoclonal clones for serotypes 7F, 18C, 19F, 
20, and 22F; this updated assay (validated using 2037 urine samples from patients with CAP or 
suspected pneumococcal disease, with a calculated clinical sensitivity of 94·3% and specificity of 
93·6% - manuscript in preparation) was used for the remainder of the study period.  Sixteen of the 
human monoclonal antibodies within the Bio-plex24 assay exhibit some cross-reactivity with specific 
non-targeted pneumococcal serotypes. A ‘checkerboard’ system for interpretation of results allows 
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serotype identification for 5 of these serotypes. In the remaining 11, based on probabilistic grounds, 
the designated serotype for analysis was determined according to the predominant serotype 
observed in national IPD data for the corresponding time period (Appendix 2).4 
During sample testing between September 2014 and August 2015 (first batch tested), the 
monoclonal antibodies targeting serotypes 7F, 20, and 22F were found to cross-react with an 
unknown substance in some urine samples. Therefore, in reporting results for samples from that 
study year, we excluded all results for serotype 7F and applied a higher diagnostic threshold for 
serotypes 20 and 22F, with results excluded if these criteria were not satisified.12  Samples from the 
four other study years were tested with an improved Bio-plex24 assay, outlined above, eliminating 
the non-specific cross-reactivity. 
Up to September 2017, bacteraemic isolates of Streptococcus pneumoniae were identified by 
standard phenotypic methods and serotyped by slide agglutination tests with latex antisera 
(ImmuLex™ Pneumotest kit) or standard factor sera (SSI Diagnostica, Denmark). From October 2017, 
confirmation of pneumococcal isolate identification and serotype prediction was performed by bio-
informatical methods following DNA extraction and whole genome sequencing,14 with the exception 
of serotypes within serogroup 24 which were identified by conventional methods using antisera.15 
Patients were considered to have pneumococcal CAP if any of the following criteria were met: a) 
positive pneumococcal UAD or b) a positive blood culture for S pneumoniae or c) pneumococcal 
serotype or cell wall polysaccharide detection by the Bio-plex24 assay. 
Statistical analysis 
Serotypes were classified according to the serotype content of vaccines:  PCV7 serotypes (serotypes 
4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13non7 serotypes (serotypes 1, 3, 5, 6A/C, 7F/A, 19A), 
PPV23non13 serotypes (serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F), and non-vaccine-
type (NVT) serotypes (comprising a) any non-PCV13, non-PPV23 serotype and b) ‘untyped’ 
pneumococcal disease; Binax UAD positive without subsequent serotype identification, or Bio-plex24 
positive for cell wall polysaccharide only.)  
Annual incidence rates were derived from mid-year estimates from the Office for National Statistics 
for the Greater Nottingham area, including local population data stratified by age group (16-49, 50-
64, 65-74, 75-84, ≥85 years.) Trends between 2013 and 2018 comparing overall incidence of CAP, 
pneumococcal CAP, and CAP according to serotype categories were examined. Additionally, serotype 
trends were compared with corresponding national IPD surveillance data.4 Poisson regression 
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models together with 95% confidence intervals were used to assess year to year variation and linear 
trends in serotype distribution.  
Clinical risk factors for pneumococcal disease were defined in accordance with PHE’s ‘Immunisation 
against Infectious Diseases’ (The Green Book).3 For analyses of groups at-risk of pneumococcal 
disease, patients with multiple serotypes that crossed vaccine groups were excluded (e.g. one or 
more positive serotype in both PCV-13 and PPV23-serotype disease groups). Baseline characteristics 
and co-morbid risk factors for PCV13- and PPV23-serotype disease were compared using Pearson’s 
chi-square or Fisher’s exact tests for categorical variables, and the Mann-Whitney U test for non-
parametric continuous variables. Likelihood ratio tests were used to determine the best model fit for 
continuous variables. Multivariate logistical regression was used to compare the independent 
association between co-morbid disease and a) PCV13- and b) PPV23-serotype disease. Purposeful 
selection of variables for inclusion in the multivariate analysis was conducted based on clinical risk 
factors outlined in PHE’s ‘Immunisation against Infectious Diseases’ (The Green Book),3 in 
conjunction with evidence from previous studies of risk factors for pneumococcal and/or vaccine 
serotype disease, and considering biological plausibility, and were specified a priori.16 Secondary 
analyses were conducted examining the risk of PCV13- and PPV23-serotype disease in:  
(a) the pneumococcal clinical risk group (defined as adults 16-64 years with ≥1 clinical risk factor for 
pneumococcal disease or age ≥65 years),  
(b) specific clinical risk groups: (1) aged 16-64 years without clinical risk factors, (2) aged 16-64 years 
with ≥1 clinical risk factor, (3) aged ≥65 years without clinical risk factors, and (4) aged ≥65 years 
with ≥1 clinical risk factor, and  
(c) individuals with increasing numbers of clinical risk factors. 
Sensitivity analyses were conducted to investigate the impact of a) the method used for serotype 
designation and b) serotype 3 disease. Statistical analyses were conducted using Stata/IC 15 
(©StataCorp. 2017). 
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RESULTS 
Study population 
During the five-year study period, of 3595 eligible patients, 158 (4·4%) patients had an alternative 
diagnosis and study consent was not obtained for 503 (14·6%). Patients without consent were older 
(median age 82·2 years, interquartile range (IQR) 70·2-88·9 years versus 71·3 years, IQR 55·8-81·2 
years, p<0·001), more often resident in care home facilities (35·0% versus 4·0%, p<0·001),  more 
likely to have chronic kidney disease (12·8% versus 8·3%, p=0·001), cerebrovascular disease (21·2% 
versus 7·7%, p<0·001), and cognitive impairment (33·6% versus 3·7%, p<0·001), and  less likely to 
have chronic respiratory disease (19·5% versus 27·9%, p<0·001) compared to the study cohort 
patients.  
Baseline characteristics 
The study cohort consisted of 2934 adults hospitalised with CAP between 2013 and 2018 (Table 1); 
median age 71·3 years (IQR 55·8-81·2 years), 1515 (51·7%) male, and pneumonia severity low, 
moderate, and high in 1377 (46·9%), 880 (30·0%), and 677 (23·1%) patients respectively. Admission 
to intensive care occurred in 225 (7·7%) cases and overall 30-day case mortality rate was 7·5% (n= 
219).  
In 538 of 2934 patients, a urine sample was not available for pneumococcal testing.  Streptococcus 
pneumoniae was identified in 1075 (36.6%) patients; Binax-NOW® test was positive in 505 (47·0%) of 
1075, Bio-plex24 in 973 (90·5%) and blood cultures in 111 (10·3%). One or more serotype was 
determined in 843 (78·4%) of 1075 patients with pneumococcal CAP; 2 serotypes were identified in 
102 patients and ≥3 serotypes in 15 patients.  
Trends in pneumococcal CAP 
The overall annual incidence of CAP over the study period was 120·4 (95% confidence interval (CI) 
116·4-124·5) per 100,000 population. Annual incidence rates are presented in Table 2. Incidence 
increased significantly over the five-year period (annual IRR 1·12, 95% CI 1·09-1·14, p<0·001) (Table 
3). Adults aged ≥85 years demonstrated the greatest relative increase (115%) between 2013 and 
2018 (annual IRR 1·24, 95% CI 1·17-1·31, p<0·001).  
The overall annual incidence of pneumococcal CAP was 37·7 (95% CI 35·3-39·8) per 100,000 
population. Pneumococcal CAP incidence rates increased over five years particularly in older age 
groups; for adults aged 65-74 years, 75-84 years, and ≥85years, annual IRR was 1·12 (95% CI 1·02-
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1·22, p=0·014), 1·20 (95% CI 1·09-1·32, p<0·001), and 1·15 (95% CI 1·03-1·28, p=0·014), respectively 
(Table 3). 
The overall annual incidence for CAP due to PCV7, PCV13non7, PPV23non13 and NVTs was 2·5 (95% 
CI 1·9-3·1), 12·2 (95% CI 11·0-13·6), 15·1 (95% CI 13·7-16·6), and 11·2 (95% CI 10·0-12·5) per 100,000 
population, respectively (Figure 1). The incidence of PCV13non7-serotype CAP (annual IRR 1·12, 95% 
CI 1·04-1·21, P=0·003) and NVT-serotype CAP (annual IRR 1·19, 95% CI 1·10-1·28, P<0·001) increased 
significantly over five years.  
Pneumococcal serotypes  
 A total of 32 different serotypes were identified; 21 were definitively identified by Bio-plex24 or 
serum agglutination of bacteraemic cases while 11 were designated based on the predominant 
serotype derived from national IPD surveillance data (Figure 2 and Appendix 2). Of the 11 designated 
serotypes, nine matched the target serotypes, one was a different vaccine serotype (6A to 6C), and 
one was a NVT (15B to 15A). PCV7 serotypes were identified in 71 (6·6%) of the 1075 patients with 
pneumococcal CAP; serotype 19F was commonest (n=25, 33·3% of PCV7 serotypes), followed by 
serotype 14 (n=17, 22·7%) and 23F (n=11, 14·7%). PCV13non7 serotypes were identified in 349 
(32·5%) patients, with serotype 3 being responsible for more than half of these cases (n=205, 56·9% 
of PCV13non7 serotypes).  
PPV23non13 serotypes were identified in 431 (40·1%) patients; serotype 8 was commonest (n=197, 
44·1% of PPV23non7 serotypes) followed by serotypes 12F (n=60, 13·4%), 11A (n= 38, 8·5%), 22F 
(n=36, 8·1%) and 9N (n=35, 7·8%). 
An NVT-serotype was identified in 321 (29·9%) patients, with serotype 15A identified in more than a 
quarter (n=80, 26·9% of NVT serotypes) while no serotype (‘untyped’ pneumococcal disease) was 
identified in 231 patients.  
Compared to national IPD data over the same period,4 proportions of serotype 3 disease were higher 
for CAP while PPV23non13-serotype disease was higher in IPD (Figure 3). The observed increase in 
serotype 3 pneumonia (annual IRR 1·28, 95% CI 1·24-1·32) was of similar magnitude to serotype 3 in 
IPD (annual IRR 1·23, 95% CI 1·12 – 1·36) (Table 6 and Figure 4). 
Persons with PCV13-serotype pneumonia 
Of 983 patients eligible for analysis (single serotype, or multiple serotypes not crossing vaccine 
serogroup classes), 325 had PCV13-serotype and 658 had non-PCV13-serotype disease 
(supplementary table 1). Increasing age (per year increase, adjusted Odds Ratio (aOR) 1·02, 95% CI 
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1·01-1·03, p<0·001) and chronic kidney disease (aOR 1·71, 95% CI 1·02-2·86, p=0·019 respectively) 
were significantly associated with higher odds of PCV13-serotype disease compared to non-PCV13-
serotype disease. Conversely, those living in residential care (aOR 0·28, 95% CI 0·10-0·75, p=0·012) or 
with active malignancy (aOR 0·52, 95% CI 0·31-0·90, p=0·019) had significantly lower odds of PCV13-
serotype disease. On multivariate analysis, patients in the pneumococcal clinical risk group (aOR 
1·73, 95% CI 1·31-2·28, p<0·001) and patients aged ≥65years with ≥1 risk factor (aOR 1·69, 95% CI 
1·24-2·30, p=0·001)  had significantly higher odds of PCV13-serotype whilst patients aged 16-64 
years without risk factors had significantly lower odds of PCV13-serotype disease (aOR 0·59, 95% CI 
0·43-0·81, P=0·001)(Table 4). 
Sensitivity analysis excluding all cases with designated serotypes (n=157) did not significantly alter 
findings. Patients >65years with 1 or more clinical risk factor were no longer at increased risk of PCV-
13 serotype disease when  cases of serotype 3 were excluded and the associations between PCV-13 
serotype disease and other risk groups were less pronounced but remained significant 
(Supplementary data).  
Persons with PPV23 serotype pneumonia  
Of 1048 patients eligible for analysis (single serotype, or multiple serotypes not crossing vaccine 
serogroup classes), 732 had PPV23-serotype and 316 had non-PPV23-serotype disease 
(supplementary table 2). There were no significant associations between risk of PPV23 serotype 
disease and individual co-morbidities identified in the multivariate analysis. On multivariate analysis 
of clinical risk and PPV23 serotype disease, both the pneumococcal clinical risk group (aOR 0·65, 95% 
CI 0·48-0·88, p=0·006) and patients 16-64 years with ≥1 risk factor (aOR 0·51, 95% CI 0·35-0·73, 
p<0·001) had significantly lower odds of PPV23-serotype disease (Table 5). Patients 16-64 years 
without risk factors had significantly higher odds of PPV23-serotype disease (aOR 1·54. 95% CI 1·13-
2·10, p=0·006). 
Sensitivity analyses excluding 1) all cases with designated serotypes (n=183) and 2) all cases of 
serotype 3, from the model did not significantly alter findings.  
An exploratory analysis to identify persons at risk of PPV23non13-serotype disease found that 
patients aged 16-64 years without risk factors had significantly higher odds of PPV23non13-serotype 
disease (aOR 1·94, 95% CI 1·42-2·65, p<0·001), whilst patients aged ≥65 years with ≥1 risk factor 
(aOR 0·69, 95% CI 0·51-0·94, p=0·017) and pneumococcal clinical risk group (aOR 0·52, 95% CI 0·38-
0·70, p<0·001) had significantly lower odds of PPV23non13-serotype disease compared to non-
PPV23non13-serotype disease.  
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DISCUSSION 
The key study findings are 1) the annual incidence of adult pneumococcal CAP has increased from 
32·2 per 100,000 population in 2013 to 48·2 per 100,000 population in 2018, concurrent with 
increases in the incidence of overall CAP, 2) this increase is predominantly due to increases in 
PCV13non7- and NVT-serotype pneumonia, 3) serotype 3 accounts for more than half of 
PCV13non7-serotype pneumonia, 4) PCV13-serotype pneumonia is 73% more likely in patients in 
pneumococcal clinical risk group, while 5) PPV23-serotype pneumonia is 54% more likely in younger 
patients who are not in the pneumococcal clinical risk group.  
The epidemiology of adult pneumococcal pneumonia in Europe appears to be diverging from that 
seen in the US. We found evidence of pneumococcal infection in more than a third of adults 
hospitalised with CAP, consistent with other recent reports from Europe.17,18 In contrast, in the US, 
Streptotoccus pneumoniae has been recently implicated in only 8 - 12% of hospitalised cases of 
CAP.19,20 During 2008-2013, we had observed early indications of a decline in CAP due to PCV13 
serotypes in adults following PCV7 substitution with PCV13 in the childhood immunisation 
programme. However, our latest findings in a previously untested and unreported cohort of patients 
from Nottingham indicate that PCV13 serotypes continue to account for a large proportion (40·6%) 
of adult CAP, with serotype 3 alone comprising 47·1% of PCV13 serotype cases. Pneumococcal 
carriage studies21,22 and national surveillance of IPD5 have also observed a limited direct and indirect 
effect of PCV13 vaccination on serotype 3.  These results are consistent with data indicating the 
serotype 3 antigen within PCV13 may provide suboptimal direct and indirect protection.23 
Notwithstanding serotype 3, there appears to be a persistence of PCV13 serotypes causing CAP. 
Serotypes 3, 5 and 6A were relatively more common in CAP compared to IPD , possibly indicating a 
predilection for pneumonia (rather than IPD) with these serotypes, as also observed by others.24,25  
We identified multiple serotypes in 10.9% of patients with pneumococcal pneumonia. This is higher 
than the proportion with multiple serotypes identified in IPD cohorts.  The relevance and 
implications of this finding warrants further investigation. 
Based on data from 2008 – 2013, we previously reported that PCV13-serotype CAP was less common 
in adults in the pneumococcal clinical risk group compared to adults aged 16 – 64 years without 
clinical risk factors.26 Those data reflected the situation within the first few years after introduction 
of the childhood PCV13 immunisation programme. Since then, the burden of PCV13-serotype CAP 
has shifted and adults in pneumococcal clinical risk group are at increased risk of infection. This 
association is dominated by serotype 3 which may reflect the invasiveness potential of this serotype, 
its penchant for pneumonia (compared to IPD) and its persistent carriage amongst children and 
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adults. The influence of the recently emerged Clade II lineage (of serotype 3) in relation to clinical 
disease presentation is unclear.27,28  
A large proportion of pneumococcal CAP was due to PPV23non13-serotype pneumonia (40·2%) with 
no significant change in incidence during 2013-2018. Serotype 8 was commonest, similar to national 
IPD trends.4 Although carriage of serotype 8 in children is rare, colonisation in young adults has been 
observed and may represent the reservoir from which adult pneumococcal infections arise.29 In 
England and Wales, uptake of PPV23 vaccination in older adults and pneumococcal clinical risk 
groups has remained stable (~70%) over the study period.30 The lack of significant change in the 
incidence of PPV23non13-serotype pneumonia suggests the replacing serotypes in pneumococcal 
pneumonia are predominantly NVT serotypes not covered by either PCV13 nor PPV23 vaccines. This 
is consistent with the observed increase in incidence of NVT-serotype pneumococcal pneumonia 
both in this study, and in other cohorts.4,8  
We found the odds of PPV23-serotype CAP was higher in patients outside the pneumococcal clinical 
risk group, specifically in patients aged 16-64 years without risk factors (aOR 1·54), but lower in 
patients in the pneumococcal clinical risk group (aOR 0·61). These associations were amplified when 
the analyses were restricted to patients with PPV23non13-serotype pneumonia (aOR 2·39 and aOR 
0·42) and could reflect individual direct protection offered by PPV in ‘at-risk’ adults.31 
Strengths and limitations 
This large prospective population-based cohort study describes trends in pneumococcal serotypes 
implicated in adult pneumococcal pneumonia over the last five years, during which PCV13 replaced 
PCV7 in the national childhood immunisation programme. Unlike laboratory-based studies, our 
study population is not over-represented by patients with chronic lung disease or those requiring 
invasive respiratory procedures.25 Use of the novel Bio-plex24 assay enabled identification of PCV13 
and PPV23 serotypes in patients presenting with non-invasive disease, which is the vast majority of 
adults with CAP, compared with previous studies which have been unable to identify PPV23-non13-
serotype disease from non-invasive samples and have classified these cases as non-vaccine-type 
infection only. 
We observed an increased incidence in all-cause CAP and pneumococcal CAP over a 5 year period 
which we have interpreted as representing a true increase in disease burden. We cannot exclude the 
possibility that some of this increase may have been due to healthcare system changes resulting in a 
shift from primary to secondary care management for CAP. However, the lack of any substantial 
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change over time in the distribution of low versus high severity pneumonia on admission suggests 
this is unlikely to be a major factor.  
One limitation of this study relates to cross-reactivity of the Bio-plex24 assay. Non-specific cross-
reactivity for serotypes 7F, 18C, 20 and 22F was noted during testing of samples from September 
2014 to August 2015. We chose to report results conservatively, accepting some under-
representation of serotypes 7F, 18C, 19F, 20, and 22F for that year. Following modifications to the 
assay, this non-specific cross-reactivity did not affect results for the other 4 years. For 11 serotypes 
displaying cross-reactivity with other serotypes not targeted by the Bio-plex24 assay we designated 
cases to a single serotype based on the predominant serotype derived from national IPD data. A 
consequence of this methodology is the potential under-representation of less frequent serotypes. 
In sensitivity analyses investigating the influence of the method of serotype designation on results, 
no major differences were detected (supplementary data available on request).  Any overall under-
representation of NVT serotypes arising from serotype designation would mean that our reported 
finding of an increased incidence of NVT-serotype CAP is conservative.  
Secondly, all untyped pneumococcal isolates were considered NVT serotypes, potentially leading to 
an over-representation of NVT-serotype CAP. The impact of this on the overall findings is likely to be 
small given the high sensitivities of the serotyping methods used.    
Additionally, as this study was performed in one geographical area, the serotype trends observed 
may have been due to local/regional epidemiological changes and our findings may not be 
applicable to other populations. Nevertheless, the main findings are consistent with trends observed 
from national IPD data. 
Implications 
We report an increase in pneumococcal CAP, predominantly due to increases in NVT serotypes and 
serotype 3. Pneumococcal vaccines targeting emerging serotypes are needed.  
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TABLE 1: Baseline characteristics, disease severity, and outcomes of community-acquired 
pneumonia (CAP) cohort and pneumococcal CAP cohort 
      CAP cohort   Pneumococcal CAP cohort 
Patients   2934   1075 
            
Demographics         
  Age, years (IQR)   
71·3 (55·8-
81·2)   69·3 (53·9-80·1) 
  16-49 years   522 (17·8)   214 (20·0) 
  50-64 years   590 (20·1)   228 (21·2) 
  65-74 years   610 (20·8)   246 (22·9) 
  75-84 years    757 (25·8)   226 (21·0) 
  ≥85 years    455 (15·5)   161 (14·9) 
  Male   1515 (51·7)   513 (47·8) 
  Care Home Resident   116 (4·0)   35 (3·3) 
            
Comorbid disease         
  Smoking status#         
  Never smoker   836 (29·5)   292 (28·0) 
  Ex-smoker   1311 (46·3)   438 (42·0) 
  Current smoker   685 (24·1)   314 (30·1) 
  Alcohol excess    80 (2·7)   42 (3·9) 
  Malignancy   269 (9·2)   91 (8·5) 
  Liver disease   48 (1·6)   24 (2·2) 
  Kidney disease   244 (8·3)   83 (7·7) 
  Chronic heart disease   460 (15·7)   145 (13·5) 
  Congestive cardiac failure   185 (6·3)   64 (6·0) 
  Ischaemic heart disease   321 (10·9)   101 (9·4) 
  
Chronic lung disease (excluding 
asthma)   819 (27·9)   292 (27·2) 
  COPD   723 (24·6)   261 (24·3) 
  Asthma   312 (10·6)   122 (11·4) 
  Diabetes Mellitus   469 (16·0)   163 (15·2) 
  Cerebrovascular disease    225 (7·7)   82 (7·6) 
  Cognitive impairment   107 (3·7)   36 (3·4) 
  Immunocompromise    109 (3·7)   47 (4·4) 
            
Disease Severity         
  CURB-65 0-1   1377 (46·9)   483 (44·9) 
  CURB-65 2   880 (30·0)   320 (29·8) 
  CURB-65 ≥3   677 (23·1)   272 (25·3) 
            
Outcomes         
  Critical Care admission   225 (7·7)   108 (10·1) 
  30-day mortality   219 (7·5)   54 (5·0) 
 
Data are presented as n (%) or median (interquartile range). COPD: chronic obstructive pulmonary disease; CURB-65: 
confusion, urea >7 mmol.L-1, respiratory rate >30 breaths.min-1, blood pressure <90mmHg [systolic] <60mmHg [diastolic], 
age ≥65years. #: Data regarding smoking status available for 2832 and 1040 participants in the CAP cohort and 
Pneumococcal CAP cohort respectively.  
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TABLE 2: Incidence rates of community-acquired pneumonia (CAP), pneumococcal CAP, and CAP due to vaccine and non-vaccine groups by study year 
  Patient 
age, 
years 
Year 6, 2013-2014 Year 7, 2014-2015 * Year 8, 2015-2016 Year 9, 2016-2017 Year 10, 2017-2018 
  
n Incidence # 95% CI n Incidence # 95% CI n Incidence # 95% CI n 
Incidence 
# 
95% CI n 
Incidence 
# 
95% CI 
All CAP   538 96·3 88·4-104·8 688 120·9 112·1-130·3 548 95·8 88·0-104·2 744 129·3 120·2-139·0 919 158·4 148·4-169·0 
16-49 91 27·3 22·0-33·5 117 34·8 28·8-41·7 114 33·7 27·8-40·5 112 33.0 27·1-39·7 102 29·9 24·4-36·3 
50-64 93 80·2 64·7-98·2 127 107·6 89·7-128·1 114 94·9 78·3-114·0 145 119·7 101·0-140·8 180 146·9 126·3-170·0 
65-74 105 181·3 148·3-219·5 148 248·7 210·3-292·2 101 164·2 133·7-199·5 131 210·4 175·9-249·6 194 310·4 268·3-357·3 
75-84 145 400·6 338·0-471·3 181 495·9 426·3-573·6 142 386·9 325·9-456·0 199 541·3 468·7-622·0 207 559·5 845·8-641·1 
≥85 104 707·5 578·1-857·2 115 766·7 633·0-920·3 77 505·4 398·9-631·7 157 1024·1 
870·2-
1197·5 
236 1522·6 
1334·5-
1729·7 
                                  
Pneumococcal 
CAP 
  180 32·2 27·7-37·3 200 35·2 30·5-40·4 166 29.0 24·8-33·8 247 42·9 37·7-48·6 282 48·6 43·1-54·6 
16-49 45 13·5 9·8-18·0 46 13·7 10·0-18·3 36 10·6 7·5-14·7 46 13·5 9·9-18·1 41 12.0 8·6-16·3 
50-64 36 31.0 21·7-43·0 40 33·9 24·2-46·2 37 30·8 21·7-42·5 55 45·4 34·2-59·1 60 49.0 37·4-63·0 
65-74 38 65·6 46·4-90·1 48 80·7 59·5-107·0 41 66·6 47·8-90·4 50 80·3 59·6-105·9 69 110·4 85·9-139-7 
75-84 28 77·3 51·4-111·8 45 123·3 89·9-165·0 34 92·6 64·2-129·5 59 160·5 122·2-207·0 63 170·3 130·8-217·8 
≥85 33 224·5 154·5-315·3 21 140.0 86·7-214·0 21 137·8 85·3-210·7 37 241·4 170·0-332·7 49 316·1 233·9-417·9 
                                  
PCV7-
serotype CAP 
  10 1·8 0·9-3·3 14 2·5 1·3-4·1 12 2·1 1·1-3·7 17 3.0 1·7-4·7 18 3·1 1·8-4·9 
16-49 1 0·3 0·0-1·7 2 0·6 0·1-2·2 3 0·9 0·2-2·6 2 0·6 0·1-2·1 1 0·3 0·0-1·6 
50-64 1 0·9 0·0-4·8 1 0·8 0·0-4·7 2 1·7 0·2-6·0 1 0·8 0·0-4·6 2 1·6 0·2-5·9 
65-74 3 5·2 1·1-15·1 3 5.0 1·0-14·7 3 4·9 1·0-14·2 6 9·6 3·5-21·0 5 8.0 2·6-18·7 
75-84 1 2·8 0·1-15·4 6 16·4 6·0-35·8 2 5·4 0·7-19·7 3 8·2 1·7-23·9 6 16·2 6·0-35·3 
≥85 4 27·2 7·4-69·7 2 13·3 1·6-48·2 2 13·1 1·6-47·1 5 32·6 10·6-76·1 4 25·8 7·0-66·1 
                                  
PCV13non7-
serotype CAP 
  64 11·5 8·8-14·6 56 9·8 7·4-12·8 51 8·9 6·6-11·7 88 15·3 12·3-18·8 90 15·5 12·5-19·1 
16-49 15 4·5 2·5-7·4 4 1·2 0·3-3·0 7 2·1 0·8-4·3 11 3·2 1·6-5·8 5 1·1 0·5-3·4 
50-64 15 12·9 7·2-21·3 8 6·8 2·9-13·4 11 9·2 4·6-16·4 14 11·6 6·3-19·4 23 18·8 11·9-28·2 
65-74 14 24·2 13·2-40·6 21 35·3 21·8-54·0 14 22·8 12·4-38·2 21 33·7 20·9-51·6 23 36·8 23·3-55·2 
75-84 12 33·1 17·1-57·9 13 35·6 19·0-60·9 8 21·8 9·4-43·0 29 78·9 52·8-113·3 22 59·5 37·3-90·0 
≥85 8 54·4 23·5-107·2 10 66·7 32·0-122·6 11 72·2 36·0-129·1 13 84·8 45·2-145·0 17 109·7 63·9-175·6 
                                  
PPV23non13-
serotype CAP 
  71 12·7 9·9-16·0 93 16·3 13·2-20·0 73 12·8 10·0-16·0 99 17·2 14·0-21·0 95 16·4 13·3-20·0 
16-49 19 5·7 3·4-8·9 27 8.0 5·3-11·7 20 5·9 3·6-9·1 23 6·8 4·3-10·2 21 6·1 3·8-9·4 
50-64 16 13·8 7·9-22·4 19 16·1 9·7-25·1 19 15·8 9·5-24·7 21 17·3 10·7-26·5 20 16·3 10·0-25·2 
65-74 13 22·5 12·0-38·4 17 28·6 16·6-45·7 16 26.0 14·9-42·2 20 32·1 19·6-49·6 22 35·2 22·1-53·3 
75-84 13 35·9 19·1-61·4 21 57·5 35·6-87·9 12 32·7 16·9-57·1 21 57·1 35·4-87·3 19 51·4 30·9-80·2 
≥85 10 68.0 32·6-125·1 9 60.0 27·4-113·9 6 39·4 14·4-85·7 14 91·3 49·9-153·2 13 83·9 44·7-143·4 
                                  
Non-vaccine-   50 9.0 6·6-11·8 55 9·7 7·3-12·6 47 8·2 6·0-10·9 70 12·2 9·5-15·4 99 17·1 13·9-20·8 
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serotype CAP 16-49 12 3·6 1·9-6·3 15 4·5 2·5-7·4 10 3.0 1·4-5·4 13 3·8 2·0-6·5 13 3·8 2·0-6·5 
50-64 9 7·8 3·5-14·7 13 11.0 5·9-18·8 7 5·8 2·3-12·0 21 17·3 10·7-26·5 19 15·5 9·3-24·2 
65-74 12 20·7 10·7-36·2 13 21·8 11·6-37·4 11 17·9 8·9-32·0 12 19·3 10·0-33·7 25 40.0 25·9-59·0 
75-84 4 11.0 3·0-28·3 11 30·1 15·0-53·9 11 30.0 15·0-53·6 16 43·5 24·9-70·7 22 59·5 37·3-90·0 
≥85 13 88·44 47·1-151·2 3 20.0 4·1-58·4 8 52·5 22·7-103·4 8 52·2 22·5-102·8 20 129.0 78·8-199·3 
 
PCV7-serotype CAP: CAP due to serotypes included in PCV7; PCV13non7-serotype CAP: CAP due to serotypes included in PCV13, excluding serotypes also included in PCV7; PPV23non13-
serotype CAP: CAP due to serotypes included in PPV23, excluding serotypes also included in PCV13; Non-vaccine-serotype CAP: CAP due to a) any non-PCV13- non-PPV23-serotype and b) 
untyped pneumococcal cases – blood culture or BINAX UAD positive without subsequent serotype identification, or Bio-plex24 assay positive for cell wall polysaccharide only.. #: per 100,000 
population 
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TABLE 3: Linear trends and variation in CAP due to serotype groups, and non-vaccine serotype CAP  
  
2013-
14 
  2014-15   2015-16 
  
2016-17   2017-18   Change in 
IRR per 
year 
    p value 
for trend 
  IRR   IRR 95% CI   IRR 95% CI   IRR 95% CI   IRR 95% CI   95% CI   
All CAP 1·0   1·26 1·12-1·41   0·99 0·88-1·12   1·34 1·20-1·50   1·64 1·48-1·83   1·12 1·09-1·14   <0·001 
Pneumococcal CAP 1·0   1·09 0·89-1·33   0·9 0·73-1·11   1·33 1·10-1·61   1·49 1·23-1·79   1·11 1·06-1·16   <0·001 
PCV7-serotype CAP 1·0   1·37 0·61-3·09   1·17 0·51-2·71   1·65 0·76-3·60   1·73 0·80-3·75   1·13 0·96-1·34   0·135 
PCV13non7-serotype CAP 1·0   0·86 0·60-1·23   0·78 0·54-1·12   1·33 0·97-1·84   1·35 0·98-1·87   1·12 1·04-1·21   0·003 
PPV23non13-serotype CAP 1·0   1·29 0·94-1·75   1.00 0·72-1·39   1·35 1·0-1·84   1·29 0·95-1·75   1·06 0·99-1·13   0·112 
Non-vaccine-serotype CAP 1·0   1·08 0·74-1·58   0·92 0·62-1·37   1·36 0·95-1·95   1·91 1·36-2·68   1·19 1·10-1·28   <0·001 
 
Data are presented as incidence rate ratio (IRR) with 95% confidence intervals. PCV7-serotype CAP: CAP due to serotypes included in PCV7; PCV13non7- serotype CAP: CAP due to serotypes 
included in PCV13, excluding serotypes also included in PCV7; PPV23non13 -serotype CAP: CAP due to serotypes included in PPV23, excluding serotypes also included in PCV13; Non-vaccine -
serotype CAP: CAP due to a) any non-PCV13-, non-PPV23- serotype and b) untyped pneumococcal cases – blood culture or BINAX UAD positive without subsequent serotype identification, or 
Bio-plex24 assay positive for cell wall polysaccharide only. 
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TABLE 4: Association between clinical risk group and PCV13-serotype disease  
  PCV13  Non-PCV13 OR (95% CI) P value aOR (95% CI) P value 
16-64 years, no clinical risk factor 72 (22·2) 208 (31·6) 0·62 (0·45-0·84) <0·001 0·59 (0·43-0·81) 0·001 
16-64 years, ≥1 risk factor 34 (10·4) 99 (15·1) 0·66 (0·44-0·99) 0·049 0·65 (0·43-0·98) 0·04 
≥65 years, no clinical risk factor 75 (23·1) 137 (20·8) 1·14 (0·83-1·57) 0·419 1·14 (0·83-1·57) 0·422 
≥65 years, ≥1 risk factor 144 (44·3) 214 (32·5) 1·65 (1·26-2·17) <0·001 1·73 (1·31-2·28) <0·001 
Pneumococcal clinical risk group* 253 (77·8) 450 (68·4) 1·62 (1·19-2·21) 0·002 1·69 (1·24-2·30) 0·001 
Number of risk factors             
0 147 (45·2) 345 (52·4) Reference   Reference   
1 114 (35·1) 212 (32·2) 1·26 (0·94-1·70)   1·29 (0·96-1·74)   
2 46 (14·2) 81 (12·3) 1·33 (0·88-2·01)   1·40 (0·93-2·12)   
>3 18 (5·5) 20 (3·0) 2·11 (1·08-4·12) 0·013# 2·14 (1·10-4·18) 0·056# 
 
Data are presented as n (%). Adjusted OR are corrected for residential care status. Bold values indicate p value <0.05. Clinical risk factors include; chronic respiratory disease, chronic heart 
disease, chronic kidney disease, chronic liver disease, immunosuppression (splenic dysfunction, haematological disease including malignancy, solid organ or bone-marrow transplant, 
immunodeficiency, HIV, or treatment with immunosuppressive therapies but not steroids), diabetes mellitus requiring therapy, splenic dysfunction, and individuals with cerebrospinal fluid 
(CSF) leaks or cochlear implants. 
*: age ≥65years or age 16-64years with ≥1 risk factor, #: p value for trend
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TABLE 5: Association between clinical risk group and PPV23-serotype disease  
  PPV23 Non-PPV23 OR (95% CI) P value aOR (95% CI) P value 
16-64 years, no clinical risk factor 223 (30·5) 70 (22·1) 1·54 (1·13-2·10) 0·006 1·54 (1·13-2·10) 0·006 
16-64 years, ≥1 risk factor 79 (10·8) 61 (19·3) 0·51 (0·35-0·73) <0·001 0·51 (0·35-0·73) <0·001 
≥65 years, no clinical risk factor 160 (21·9) 70 (22·2) 0·98 (0·72-1·35) 0·916 0·98 (0·72-1·35) 0·706 
≥65 years, ≥1 risk factor 270 (36·9) 115 (36·4) 1·02 (0·78-1·34) 0·879 1·02 (0·78-1·34) 0·685 
Pneumococcal clinical risk group* 509 (69·5) 246 (77·9) 0·65 (0·48-0·88) 0·006 0·65 (0·48-0·88) 0·006 
Number of risk factors             
0 383 (52·3) 140 (44·3) Reference   Reference   
1 221 (30·2) 129 (40·8) 0·63 (0·47-0·84)   0·63 (0·47-0·84)   
2 95 (13·0) 41 (13·0) 0·85 (0·56-1·28)   0·85 (0·56-1·28)   
>3 33 (4·5) 6 (1·9) 2·01 (0·82-4·91) 0·617# 2·01 (0·82-4·91) 0·002# 
 
Data are presented as n (%). Bold values indicate p value <0.05. Clinical risk factors include; chronic respiratory disease, chronic heart disease, chronic kidney disease, chronic liver disease, 
immunosuppression (splenic dysfunction, haematological disease including malignancy, solid organ or bone-marrow transplant, immunodeficiency, HIV, or treatment with 
immunosuppressive therapies but not steroids), diabetes mellitus requiring therapy, splenic dysfunction, and individuals with cerebrospinal fluid (CSF) leaks or cochlear implants. 
*: age ≥65years or age 16-64years with ≥1 risk factor, #: p value for trend 
Page 25 of 25 
 
TABLE 6: Incident rate ratios for pneumococcal pneumonia cohort and IPD cohort between 2013 and 2018. 
  
2013-
14 
2014-15 2015-16 2016-17 2017-18 Change in IRR per 
year (95% CI) 
p value for 
trend 
  IRR IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
National IPD cohort - serotype 3 1.0 1·42 (1·19-1·70) 1·91 (1·61-2·25) 2·27 (1·93-2·67) 2·87 (2·45-3·36) 1·28 (1·24-1·32) <0·001 
CAP cohort - serotype 3 1.0 1·53 (0·93-2·53) 0·94 (0·54-1·64) 2·21 (1·38-3·54) 2·31 (1·45-3·68) 1·23 (1·12-1·36) <0·001 
National IPD cohort - PCV7-serotype 1.0 1·12 (0·86-1·48) 1·09 (0·82-1·43) 1·26 (0·96-1·64) 1·35 (1·04-1·75) 1·07 (1·01-1·14) 0·015 
CAP cohort - PCV7-serotype 1.0 1·37 (0·61-3·09) 1·17 (0·51-2·71) 1·65 (0·76-3·60) 1·73 (0·80-3·75) 1·13 (0·96-1·34) 0·135 
National IPD cohort - PCV13non7-serotype 1.0 1·20 (1·08-1·33) 1·16 (1·04-1·29) 1·29 (1·17-1·43) 1·48 (1·34-1·64) 1·09 (1·07-1·11) <0·001 
CAP cohort - PCV13non7-serotype 1.0 0·86 (0·60-1·23) 0·78 (0·54-1·12) 1·35 (0·98-1·86) 1·35 (0·98-1·87) 1·12 (1·04-1·21) 0·003 
National IPD cohort - PPV23non13-serotype 1.0 1·43 (1·34-1·53) 1·80 (1·69-1·91) 1·83 (1·72-1·95) 1·88 (1·77-2·00) 1·15 (1·13-1·16) <0·001 
CAP cohort - PPV23non13-serotype 1.0 1·29 (0·94-1·75) 1·00 (0·72-1·39) 1·35 (1·00-1·84) 1·29 (0·95-1·75) 1·06 (0·99-1·13) 0·112 
National IPD cohort - Non-vaccine-serotype 1.0 1·12 (1·01-1·22) 1·05 (0·96-1·16) 1·16 (1·06-1·27) 1·32 (1·20-1·44) 1·06 (1·04-1·08) <0·001 
CAP cohort - Non-vaccine serotype 1.0 1·04 (0·65-1·65) 0·84 (0·51-1·36) 1·17 (0·74-1·82) 2·06 (1·38-3·08) 1·21 (1·10-1·33) <0·001 
 
Data are presented as incidence rate ratio (IRR) with 95% confidence intervals. IPD: invasive pneumococcal disease; CAP: Community-acquired pneumonia; PCV7-serotype: pneumococcal 
disease due to serotypes included in PCV7; PCV13non7- serotype: pneumococcal disease due to serotypes included in PCV13, excluding serotypes also included in PCV7; PPV23non13 -
serotype: pneumococcal disease due to serotypes included in PPV23, excluding serotypes also included in PCV13;  
CAP cohort: Non-vaccine-serotype: pneumococcal disease due to a) any non-PCV13-, non-PPV23- serotype and b) untyped pneumococcal cases – blood culture or BINAX UAD positive without 
subsequent serotype identification, or Bio-plex24 assay positive for cell wall polysaccharide only ‘ 
National IPD cohort: Non-vaccine-serotype: pneumococcal disease due to any non-PCV13-, non-PPV23-serotype case 
